Table 1 Clinical characteristics of 20 R/R B-ALL patients
Patient number | Age | Gender | ECOG | Leukemia type and genetic abnormalities | Disease status | BM blasts burden | Prior lines of treatment | EMD status |
|---|---|---|---|---|---|---|---|---|
1 | 31 | Female | 1 | Ph-ALL | Refractory | 56.0% | 2 | No |
2 | 23 | Female | 1 | Ph+ALL*(T315I mutation) | Relapse | 38.6% | 2 | No |
3 | 50 | Male | 0 | Ph-ALL | Refractory | 3.0% | 2 | No |
4 | 18 | Male | 0 | Ph-ALL | Relapse | 30.5% | 2 | No |
5 | 44 | Male | 0 | Ph-ALL | Refractory | 24.5% | 2 | No |
6 | 16 | Male | 0 | Ph-ALL (IKZF1 deletion, NRAS mutation) | Refractory | 26.0% | 3 | No |
7 | 10 | Male | 0 | Ph-ALL (E2A-PBX1 rearrangement) | Relapse | 4.5% | 2 | No |
8 | 16 | Male | 0 | Ph+ALL (T315I mutation) | Relapse | 83.5% | 2 | No |
9 | 24 | Male | 1 | Ph-ALL | Relapse | 40.5% | 2 | No |
10 | 9 | Male | 0 | Ph-ALL (IgH rearrangements) | Refractory | 40.5% | 2 | No |
11 | 7 | Male | 0 | Ph-ALL | Relapse | 7.5% | 2 | No |
12 | 9 | Female | 0 | Ph-ALL (ETV6-RUNX1 rearrangement) | Relapse | 10.0% | 2 | No |
13 | 19 | Male | 0 | Ph-like ALL (EBF1-PDGFRB rearrangement, IKZF1 deletion) | Relapse | 75.0% | 2 | Yes |
14 | 14 | Female | 0 | Ph-ALL | Refractory | 32.5% | 3 | No |
15 | 18 | Male | 0 | Ph-like ALL (PAX5-JAK2 rearrangement, TP53 deletion) | Relapse | 73.5% | 1 | No |
16 | 43 | Female | 1 | Ph-ALL | Refractory | 60.5% | 2 | No |
17 | 11 | Female | 0 | Ph-ALL | Refractory | 5.0% | 2 | No |
18 | 3 | Female | 0 | Ph-ALL (TP53 mutation, IKZF1 deletion) | Refractory | 6.0% | 5 | No |
19 | 52 | Female | 0 | Ph-ALL | Refractory | 96.0% | 2 | No |
20 | 40 | Male | 0 | Ph-ALL (IKZF1 deletion) | Refractory | 64.5% | 2 | Yes |